

# CRAFTING

PROSPERITY

## Performance Review for the Three Months ended 30<sup>th</sup> June 2025

### Overview

The Group sustained its positive trajectory from the previous year, delivering a resilient performance for the quarter achieving a cumulative revenue of Rs. 28.5 billion. Operating profit and earnings grew by 6.9 % and 26.1% respectively, reaching Rs. 2.1 billion and Rs. 1.2 billion for the quarter. The year on year improvement in Group earnings was driven by stronger topline growth, improved gross profit margins, and reduced finance costs. Revenue in the Consumer Brands Sector recorded a marginal decline compared to the previous year, primarily due to the impact of prior-year strategic price adjustments.

During the quarter, the equity market demonstrated strong momentum, with the All Share Price Index (ASPI) and the S&P SL20 Index posting year-on-year gains of 48.4% and 49.2%, respectively, reflecting improved investor sentiment. Following the share sub-division, Hemas share continued its upward trajectory, supported by heightened interest from local retail investors. The share closed the quarter at Rs. 30.50, marking a robust year-on-year gain of 83.1%.

### Operating Environment

Sri Lanka made a significant stride in its economic recovery during the quarter, with the International Monetary Fund (IMF) Board completing the fourth review under the Extended Fund Facility (EFF). This milestone facilitated the disbursement of the fifth tranche amounting to USD 315 million, bringing the total disbursement under the programme to approximately USD 1.7 billion. Concurrently, the Government achieved progress on its external debt restructuring efforts, successfully renegotiating bilateral debt obligations with France and India—further strengthening the country's external debt profile.

Deflationary trends that began in September 2024 persisted into the quarter, though signs of moderation were observed towards the end of the period, with headline inflation recorded at -0.6%. The Sri Lankan Rupee depreciated marginally by 1.9% against the USD, supported by continued foreign inflows, Central Bank intervention, and subdued inflationary pressures. Reflecting the soft inflation outlook, the Central Bank reduced the Overnight Policy Rate by 25 basis points in May 2025, resulting in a further decline in the Average Weighted Prime Lending Rate (AWPLR) to 8.1% per annum.

Sri Lanka's economy recorded a year on year growth of 4.8% in the first quarter of 2025, marking the seventh consecutive quarter of positive growth since the third quarter of 2023. This sustained momentum was driven by exchange rate stability and lower interest rates, although growth in the agricultural sector remained subdued.

Global economic growth is expected to moderate in 2025, impacted by escalating trade barriers, increased policy uncertainty in key markets, and ongoing geopolitical tensions. In commodity markets, although crude oil and palm oil prices remained lower year on year, prices of both commodities trended upward during the quarter.

LKR Million

### Quarterly Financial Snapshot

	FY26 Q1	Vs FY25 Q1	Vs FY25 Q4
Consumer Brands	8,636.1	-2.6%	-14.4%
Healthcare	19,391.3	20.2%	-1.8%
Mobility	494.9	4.0%	1.6%
Other	3.6	-30.0%	-86.7%
<b>Revenue</b>	<b>28,525.8</b>	<b>12.0%</b>	<b>-6.0%</b>
<b>Gross Profit</b>	<b>8,600.8</b>	<b>13.0%</b>	<b>-7.7%</b>
Gross Profit Margin	30.2%	0.3 pt	-0.6 pt
<b>EBITDA</b>	<b>2,626.9</b>	<b>10.3%</b>	<b>-40.3%</b>
EBITDA Margin	9.2%	-0.1 pt	-5.3 pt
<b>Operating Profit</b>	<b>2,064.0</b>	<b>6.9%</b>	<b>-46.0%</b>
Operating Profit Margin	7.2%	-0.3 pt	-5.4 pt
Net Interest Cost	(111.6)	-48.0%	-52.0%
Income Tax Expenses	(697.1)	-2.3%	-26.2%
<b>Earnings</b>	<b>1,191.9</b>	<b>26.1%</b>	<b>-53.7%</b>

## Consumer Brands

The Sector continued to strengthen its market presence through focused sales and promotional initiatives, which supported volume recovery across key categories. Despite a marginal 2.6% year-on-year decline in revenue primarily due to price adjustments taken previously that were driven by input cost deflation, the sector maintained its profitability through a combination of portfolio mix optimisation and sustained process improvements. Operating profit stood at Rs. 719.1 million, while earnings grew by 13.6 % to Rs. 665.6 million.

### *Home and Personal Care – Sri Lanka*

Beauty and Personal Care recorded encouraging volume growth during the quarter, driven by strong performance in key brands such as *Vivya*, *Velvet* Body Lotion, *Dandex*, and *Goya* Body Mist and Lotion. In contrast, Personal Wash and Home Care segments experienced moderate volume declines.

In line with the evolving consumer needs, the Group expanded its Personal Care portfolio with the launch of *Gold* Hair Wax, further strengthening its presence in the male grooming segment.

Clogard received notable recognition during the quarter, being featured in the Sri Lanka and Maldives Edition of *Essentials in Modern Marketing by Kotler Impact Inc.* This accolade underscores the brand's strong consumer relevance, local market insight, and consistent track record of innovation – positioning Clogard as a benchmark for marketing excellence in the region.

Demonstrating its commitment to long-term capability building, Hemas Consumer Brands entered into a strategic partnership with the Institute of Supply and Materials Management (ISMM) aimed at advancing innovation, professional development, and sustainable growth within Sri Lanka's supply chain ecosystem. The collaboration is designed to bridge the gap between industry and academia, equipping future professionals with the skills and exposure needed to lead with purpose and impact.

### *Consumer Brands International*

Bangladesh's macroeconomic environment continued to improve, with headline inflation easing to 8.5% in June 2025. Currency stability was supported by strong export performance and a notable increase in remittance inflows, which contributed to the strengthening of foreign exchange reserves. However, the external sector may encounter renewed pressure following the introduction of a 20% reciprocal tariff on all Bangladeshi exports to the United States, effective 7th August 2025—posing potential risks to future export growth.

The business maintained its positive momentum during the quarter, with earnings growth driven by both increased revenues and margin expansion. Performance benefitted from a favourable sales mix, reflecting a strategic shift toward higher-margin product categories. Margin improvements were further supported by reduced input costs, enabled by proactive and disciplined procurement efforts.

### *Learning*

Atlas sustained its market leadership across key categories, with most segments recording year on year revenue growth during the quarter. To reinforce its position and boost stationery sales, the business launched an innovative island-wide promotion campaign during the period.

The Atlas *PlayPlaz* range of educational aids and toys, initially launched in the Western Province last year, has now been made available island wide. To date over 3,600 preschool teachers have been trained on the effective use of these products, raising awareness and empowering educators to serve as brand ambassadors.

## Healthcare

The Healthcare sector delivered strong revenue growth of 20.2 % during the first quarter, reflecting the strength and resilience of its diversified portfolio. All segments—hospitals, pharmaceutical distribution and manufacturing contributed positively to this performance. This growth momentum was supported by continued investments aimed at enhancing service quality and expanding product offerings. The Sector reported quarterly revenue of Rs. 19.4

billion, with operating profit of Rs. 1.7 billion, and earnings of Rs. 1.1 billion, representing a 29.4% and 26.8% year-on-year increase respectively.

### *Pharmaceuticals*

Both Pharmaceutical Distribution and Manufacturing segments recorded significant improvements in profitability during the period, underpinned by robust topline growth, margin expansion, and disciplined operational execution.

During the quarter, Hemas Pharmaceuticals (Pvt) Ltd (HPPL), the leading pharmaceutical distributor in Sri Lanka, further reinforced its commitment to expanding access to quality, world class healthcare solutions by introducing several new therapies in the lipid and blood pressure regulatory segments.

With the objective of unlocking greater group synergies and sharpening Morison's focus on core manufacturing, Morison transitioned its distributed pharmaceutical agency operations to HPPL. The move leverages HPPL's specialised commercial capabilities, allowing Morison to focus on scaling its manufacturing operations while enhancing integration and value creation across the Hemas Healthcare sector. Furthermore, the third batch of the Certificate Training Course in Diabetes Care, conducted in partnership with the Sri Lanka College of Endocrinologists (SLCE) with the objective of upgrading skills in the management of diabetes among primary healthcare physicians, was successfully launched during the quarter. The Sri Lanka Pharma Manufacturers' Association (SLPMA), in which Morison is an active member, recently presented a strategic blueprint to the Government, outlining a comprehensive set of actionable recommendations, with the objective of positioning pharmaceutical manufacturing as a key thrust industry in Sri Lanka.

The Government has recently issued a Gazette (No. 2446/34), introducing price regulation including establishing maximum retail prices for medicines. The implementation of this mechanism is expected to impact the selling prices of pharmaceuticals, which are currently market determined.

### *Hospitals*

Redefining Sri Lanka's private healthcare landscape, Hemas *Health Plus*, a purpose-built facility which merges advanced clinical services with comfort, convenience in a lifestyle-integrated approach was opened in Wattala. Anchored by a tertiary hospital framework, the facility features specialised centers including the country's first private-sector paediatric liver unit, a premium cosmetic care center, and child-friendly paediatrics and wellness hubs. It offers seamless access to diagnostics, emergency care, and specialist consultations under one roof.

In a significant advancement in non-invasive diagnostics, Hemas Hospitals Wattala introduced Sri Lanka's first Echosens FibroScan Expert 630 system, a globally recognised standard for liver health assessment. This state-of-the-art technology enables early detection, diagnosis, and monitoring of liver diseases and marks an important step toward establishing a comprehensive liver care centre. The initiative strengthens the hospital's clinical capabilities and broadens access to specialised, high-quality liver care in the country.

### *Mobility*

The Maritime segment revenue grew during the quarter, primarily supported by increased cargo volumes, while average freight rates remained stable. The segment continues to monitor global macroeconomic and geopolitical developments closely, including changes in tariff policies, disruption along the Red Sea route and broader supply chain realignments that may impact freight rates and cargo flows.

In the Aviation segment, revenue from cargo operations increased, driven by higher volumes and improved average freight rates. However, passenger volumes declined due to heightened competition within the industry. As part of ongoing efforts to enhance its service offering, Emirates will introduce its retrofitted four-class Boeing 777 on the Dubai Colombo route. This addition will mark the second daily Emirates flight to Sri Lanka featuring Premium Economy seats, offering an elevated travel experience.

The Mobility sector posted revenue growth of 4.0% year-on-year, reaching Rs. 494.9 million, primarily due to improved performance in cargo operations. Operating profit and earnings posted Rs. 298.2 million and Rs. 148.3 million respectively.

## Leading with ESG

In alignment with its long-term sustainability roadmap, the Group continued to drive progress across its environmental priorities, reinforcing its commitment to operational sustainability and responsible resource stewardship. Strategic interventions in plastic waste management resulted in the collection of 281,534 kg of plastic, with 1.8 million kg of plastic collected to date as a part of Group's effort to collect back 100% of its plastic sent to the market.

Targeted efficiency upgrades and process improvements led to a 1.8% reduction in Group water intensity, reflecting ongoing efforts to optimise resource consumption across operations. The Group continued to advance its transition to renewable energy, with 9.0% of total electricity consumption now derived from clean energy sources, primarily through solar installations at key operational sites.

During the quarter, the Group continued to empower communities through initiatives focused on education, health, and economic inclusion. Over 19,000 children and teachers benefited from digital learning and teacher training programs, while early childhood education was expanded with two new preschools. Health and wellbeing programs reached over 4,700 individuals through preventive care and awareness initiatives. In support of vulnerable communities, more than 2,000 people were engaged through livelihood support and wellbeing programs, donations for patients, and nutrition interventions for over 1,200 preschoolers across 12 districts.

## Outlook

Deflationary pressures are expected to ease, supported by the 15% electricity tariff increase implemented in June and a gradual rise in global commodity prices. Moreover, in a significant development for Sri Lanka's exports, United States has further reduced tariffs on Sri Lankan exports to 20%, down from the initially announced rate of 44% in April. The new tariff structure will come into effect from 7th of August and while it still presents a material risk to export competitiveness, the significant tariff reduction is expected to provide a measure of relief to Sri Lankan exporters.

I would like to take this opportunity to sincerely thank Mr. Ravi Jayasekera for his leadership during the transition period, which enabled the Group to maintain stability and performance.

As I take on this responsibility, I am encouraged by the signs of macroeconomic stabilisation and remain confident that our strategic direction will drive sustainable growth for the Group in the year ahead. We are currently evaluating overseas expansion opportunities and the extension of the Thalawathugoda hospital—ventures that are aligned with our long-term growth priorities and designed to unlock scale and value across the portfolio. Further, there will also be continued focus on enhancing internal efficiencies through initiatives which were rolled out last year, such as optimising the Group's operating structure, upgrading the IT infrastructure and driving digital transformation across the Group.

I look forward to working closely with our teams and partners as we navigate this next phase—focused, grounded, and committed to creating long-term value for all our stakeholders.



**Ashish Chandra**

**Group Chief Executive Officer**

**August 06, 2025**

**Colombo**

## CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Three Months Ended 30 June		
	2025	2024	Change %
<b>Revenue from Contracts with Customers</b>	<b>28,525,845</b>	25,476,163	12.0%
Cost of Sales	(19,925,030)	(17,865,903)	11.5%
<b>Gross Profit</b>	<b>8,600,815</b>	7,610,260	13.0%
Other Operating Income	224,962	199,010	13.0%
Selling and Distribution Expenses	(2,407,702)	(2,252,457)	6.9%
Administrative Expenses	(4,302,639)	(3,636,154)	18.3%
Share of Results of Equity Accounted Investees (Net of Tax)	(51,437)	9,822	-623.7%
<b>Operating Profit</b>	<b>2,063,999</b>	1,930,481	6.9%
Finance Cost	(251,082)	(373,994)	-32.9%
Finance Income	139,502	159,402	-12.5%
<b>Profit Before Tax</b>	<b>1,952,419</b>	1,715,889	13.8%
Income Tax Expense	(697,139)	(713,593)	-2.3%
<b>Profit for the Period</b>	<b>1,255,280</b>	1,002,296	25.2%
<b>Attributable to:</b>			
Equity Holders of the Parent	1,191,893	945,559	26.1%
Non-Controlling Interests	63,387	56,737	11.7%
	<b>1,255,280</b>	1,002,296	25.2%
	<b>LKR</b>	<b>LKR</b>	
<b>Earnings Per Share</b>			
Basic	0.40	0.32	
Diluted	0.40	0.32	
<b>Dividend Per Share*</b>	<b>0.70</b>	3.00	

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.  
*\*Dividend per share, post 1:5 share split*

## CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Three Months Ended 30 June	
	2025	2024
Profit for the Period	1,255,280	1,002,296
<b>Other Comprehensive Income</b>		
<b>Other Comprehensive Income to be Reclassified to Profit or Loss in Subsequent Periods</b>		
Exchange Differences on Translation of Foreign Operations	(45,385)	(53,004)
	(45,385)	(53,004)
<b>Other Comprehensive Income not to be Reclassified to Profit or Loss in Subsequent Periods</b>		
Net Profit /(Loss) on Financial Assets at FVOCI (Equity)	(222)	4,720
	(222)	4,720
<b>Other Comprehensive Income for the Period, Net of Tax</b>	(45,607)	(48,284)
<b>Total Comprehensive Income for the Period, Net of Tax</b>	<b>1,209,673</b>	<b>954,012</b>
<b>Attributable to:</b>		
Equity Holders of the Parent	1,146,286	897,275
Non-Controlling Interests	63,387	56,737
	<b>1,209,673</b>	<b>954,012</b>

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	As at 30 June		As at 31 March
	2025	2024	2025
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
Property, Plant and Equipment	24,486,439	20,127,094	24,396,797
Investment Properties	4,305,782	4,013,285	4,305,782
Right-of-Use Assets	2,000,770	1,271,944	1,889,329
Intangible Assets	3,316,041	3,263,279	3,333,057
Investment in Equity Accounted Investees	2,240,656	1,482,449	2,153,877
Lease Receivables	14,673	38,475	22,648
Other Non-Current Financial Assets	265,935	198,954	254,797
Deferred Tax Asset	185,707	486,416	228,746
	36,816,003	30,881,896	36,585,033
<b>Current Assets</b>			
Inventories	22,528,565	24,520,090	21,182,560
Trade and Other Receivables	25,415,892	25,152,559	25,971,470
Tax Recoverable	285,149	404,448	301,130
Lease Receivables	14,019	25,145	15,369
Other Current Financial Assets	184,174	162,082	183,326
Cash and Short-Term Deposits	12,555,200	13,777,546	12,578,510
	60,982,999	64,041,870	60,232,365
Assets Held for Sale	11,231	-	73,128
<b>Total Assets</b>	97,810,233	94,923,766	96,890,526
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Stated Capital	7,824,276	7,797,979	7,824,276
Other Capital and Revenue Reserves	81,406	104,911	75,567
Other Components of Equity	8,425,688	7,452,959	8,471,295
Retained Earnings	32,510,567	27,198,407	33,409,249
<b>Equity Attributable to Equity Holders of the Parent</b>	48,841,936	42,554,256	49,780,387
Non-Controlling Interests	603,432	744,566	540,045
<b>Total Equity</b>	49,445,368	43,298,822	50,320,432
<b>Non-Current Liabilities</b>			
Interest-Bearing Loans and Borrowings	2,523,276	5,044,745	4,617,055
Other Non-Current Financial Liabilities	275,375	279,505	275,375
Deferred Tax Liability	3,537,799	2,963,010	3,473,577
Employee Benefit Liability	1,599,893	1,407,394	1,561,558
	7,936,343	9,694,654	9,927,565
<b>Current Liabilities</b>			
Trade and Other Payables	31,826,321	30,301,485	31,940,411
Dividend Payable	2,090,576	1,790,719	-
Income Tax Liabilities	1,307,619	1,553,559	1,440,936
Interest-Bearing Loans and Borrowings	4,828,387	6,058,993	2,939,338
Bank Overdraft	370,960	2,225,534	317,185
	40,423,863	41,930,290	36,637,870
Liabilities Associated with Assets Held for Sale	4,659	-	4,659
<b>Total Equity and Liabilities</b>	97,810,233	94,923,766	96,890,526
<b>Net Assets per share - (LKR)</b>	16.35	14.26	16.67

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

These financial statements are in compliance with the requirements of the Companies Act No. 07 of 2007.



**Moiz Rehmanjee**

Group Chief Financial Officer

The Board of Directors is responsible for these financial statements.  
Signed for and on behalf of the Board by,



**Husein Esufally**

Chairman  
Colombo

August 06, 2025



**Ashish Chandra**

Group Chief Executive Officer



## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Attributable to Equity Holders of the Parent								Non - Controlling Interest	Total Equity
	Stated Capital	Other Capital & Revenue Reserves	Other Component of Equity				Retained Earnings	Total		
			Revaluation Reserve	Foreign Currency Translation Reserve	Fair Value Reserve of Financial Assets at FVOCI	Cash Flow Hedge Reserve				
As at 1 April 2024	7,783,875	103,084	7,721,486	409,292	(44,052)	(585,483)	28,043,567	43,431,769	687,829	44,119,598
Profit for the Period	-	-	-	-	-	-	945,559	945,559	56,737	1,002,296
Other Comprehensive Income	-	-	-	(53,004)	4,720	-	-	(48,284)	-	(48,284)
Total Comprehensive Income	-	-	-	(53,004)	4,720	-	945,559	897,275	56,737	954,012
Final Dividend - 2023/24	-	-	-	-	-	-	(1,790,719)	(1,790,719)	-	(1,790,719)
Exercise of ESOS	14,104	-	-	-	-	-	-	14,104	-	14,104
Share Based Payments	-	1,827	-	-	-	-	-	1,827	-	1,827
As at 30 June 2024	7,797,979	104,911	7,721,486	356,288	(39,332)	(585,483)	27,198,407	42,554,255	744,566	43,298,821
As at 1 April 2025	7,824,276	75,567	8,685,066	334,688	(20,533)	(527,926)	33,409,249	49,780,387	540,045	50,320,432
Profit for the Period	-	-	-	-	-	-	1,191,893	1,191,893	63,387	1,255,280
Other Comprehensive Income	-	-	-	-	(45,385)	(222)	-	(45,607)	-	(45,607)
Total Comprehensive Income	-	-	-	-	(45,385)	(222)	1,191,893	1,146,286	63,387	1,209,673
Final Dividend - 2024/25	-	-	-	-	-	-	(2,090,576)	(2,090,576)	-	(2,090,576)
Share Based Payments	-	5,839	-	-	-	-	-	5,839	-	5,839
As at 30 June 2025	7,824,276	81,406	8,685,066	334,688	(65,918)	(528,148)	32,510,567	48,841,936	603,432	49,445,368

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

## COMPANY STATEMENT OF PROFIT OR LOSS

	Three Months Ended 30 June		
	2025	2024	Change %
<b>Revenue from Contracts with Customers</b>	<b>439,305</b>	401,644	9.4%
Cost of Sales	-	-	-
<b>Gross Profit</b>	<b>439,305</b>	401,644	9.4%
Other Operating Income	2,719	1,338	103.2%
Administrative Expenses	(529,283)	(448,924)	17.9%
<b>Operating Loss</b>	<b>(87,259)</b>	(45,942)	-89.9%
Finance Cost	(54,808)	(62,634)	-12.5%
Finance Income	508	598	-15.1%
<b>Loss Before Tax</b>	<b>(141,559)</b>	(107,978)	-31.1%
Income Tax Expense	(16,084)	(45,073)	-64.3%
<b>Loss for the Period</b>	<b>(157,643)</b>	(153,051)	-3.0%

## COMPANY STATEMENT OF COMPREHENSIVE INCOME

	Three Months Ended 30 June	
	2025	2024
Loss for the Period	(157,643)	(153,051)
<b>Other Comprehensive Income</b>		
Net Gain/ (Loss) on Financial Assets at FVOCI	(520)	850
<b>Other Comprehensive Income for the Period, Net of Tax</b>	<b>(520)</b>	850
<b>Total Comprehensive Income for the Period, Net of Tax</b>	<b>(158,163)</b>	(152,201)

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

## COMPANY STATEMENT OF FINANCIAL POSITION

	As at 30 June		As at 31 March
	2025	2024	2025
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
Property, Plant and Equipment	76,545	87,688	82,544
Investment Properties	1,260,522	1,143,000	1,260,522
Right-of-Use Assets	150,303	48,200	-
Intangible Assets	29,138	17,933	30,712
Investment in Subsidiaries	19,261,226	18,347,946	19,116,227
Other Non-Current Financial Assets	29,431	21,530	21,322
	20,807,165	19,666,297	20,511,327
<b>Current Assets</b>			
Trade and Other Receivables	536,386	643,837	562,781
Tax Recoverable	25,756	23,199	33,005
Other Current Financial Assets	4,288	19,208	23,455
Cash and Short-Term Deposits	135,582	17,122	84,078
	702,012	703,366	703,318
<b>Total Assets</b>	<b>21,509,177</b>	<b>20,369,663</b>	<b>21,214,646</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Stated Capital	7,824,276	7,797,979	7,824,276
Other Capital and Revenue Reserves	302,757	326,263	296,918
Other Components of Equity	6,468	3,695	6,988
Retained Earnings	7,299,932	6,885,198	9,548,151
<b>Total Equity</b>	<b>15,433,433</b>	<b>15,013,135</b>	<b>17,676,333</b>
<b>Non-Current Liabilities</b>			
Interest-Bearing Loans and Borrowings	302,750	475,750	346,000
Deferred Tax Liability	304,757	265,683	296,172
Employee Benefit Liability	59,757	40,997	58,572
	667,264	782,430	700,744
<b>Current Liabilities</b>			
Trade and Other Payables	1,043,393	769,547	931,090
Dividend Payable	2,090,576	1,790,719	-
Interest-Bearing Loans and Borrowings	2,219,738	1,793,619	1,842,217
Bank Overdraft	54,773	220,213	64,262
	5,408,480	4,574,098	2,837,569
<b>Total Equity and Liabilities</b>	<b>21,509,177</b>	<b>20,369,663</b>	<b>21,214,646</b>
<b>Net Assets per share - (LKR)</b>	<b>5.17</b>	<b>5.03</b>	<b>5.92</b>

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

These financial statements are in compliance with the requirements of the Companies Act No. 07 of 2007.



**Moiz Rehmanjee**  
Group Chief Financial Officer

The Board of Directors is responsible for these financial statements.  
Signed for and on behalf of the Board by,



**Husein Esufally**  
Chairman  
Colombo  
August 06, 2025



**Ashish Chandra**  
Group Chief Executive Officer

## COMPANY STATEMENT OF CHANGES IN EQUITY

	Stated Capital	Other Capital Reserves	Other Components Of Equity Fair Value Reserve of Financial Assets at FVOCI	Retained Earnings	Total Equity
<b>As at 1 April 2024</b>	<b>7,783,875</b>	<b>324,435</b>	<b>2,845</b>	<b>8,828,968</b>	<b>16,940,123</b>
Loss for the Period	-	-	-	(153,051)	(153,051)
Other Comprehensive Income	-	-	850	-	850
<b>Total Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>850</b>	<b>(153,051)</b>	<b>(152,201)</b>
Share Based Payments	-	1,827	-	-	1,827
Exercise of Share Options	14,104	-	-	-	14,104
Final Dividend 2023/24	-	-	-	(1,790,719)	(1,790,719)
<b>As at 30 June 2024</b>	<b>7,797,979</b>	<b>326,262</b>	<b>3,695</b>	<b>6,885,198</b>	<b>15,013,135</b>
<b>As at 1 April 2025</b>	<b>7,824,276</b>	<b>296,918</b>	<b>6,988</b>	<b>9,548,151</b>	<b>17,676,333</b>
Loss for the Period	-	-	-	(157,643)	(157,643)
Other Comprehensive Income	-	-	(520)	-	(520)
<b>Total Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>(520)</b>	<b>(157,643)</b>	<b>(158,163)</b>
Share Based Payments	-	5,839	-	-	5,839
Final Dividend 2024/25	-	-	-	(2,090,576)	(2,090,576)
<b>As at 30 June 2025</b>	<b>7,824,276</b>	<b>302,757</b>	<b>6,468</b>	<b>7,299,932</b>	<b>15,433,433</b>

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

## STATEMENT OF CASH FLOWS

Three Months Ended 30 June	Group		Company	
	2025	2024	2025	2024
<b>Operating Activities</b>				
Profit/(Loss) Before Taxation from Continuing Operations	1,952,419	1,715,889	(141,559)	(107,978)
<b>Adjustments for,</b>				
Depreciation	450,465	365,621	6,761	7,232
Amortisation of Right-of-Use Assets	93,441	68,429	21,472	16,067
Gain on Disposal of Property, Plant and Equipment, Investment Properties	(12,840)	(3,996)	-	-
Provision for Share Based Payment Expense	5,840	3,485	2,167	1,102
Provision/ (Reversal) for Impairment of Trade and Other Receivables	23,726	27,017	(36,407)	2,566
Provision/ (Reversal) for Obsolete & Slow-Moving Stocks	37,713	(55,562)	-	-
Amortisation of Intangible Assets	18,981	17,033	1,573	3,149
Finance Cost	251,082	373,994	54,808	62,634
Finance Income	(139,502)	(159,402)	(508)	(598)
Share of Results of Equity Accounted Investees (Net of Tax)	51,437	(9,822)	-	-
Investment Income	-	-	(1)	(1)
Movement in Employee Benefit Liability	75,944	71,456	3,898	2,875
<b>Operating Cash Flows before Working Capital Changes</b>	<b>2,808,706</b>	<b>2,414,142</b>	<b>(87,796)</b>	<b>(12,952)</b>
<b>Working Capital Adjustments</b>				
(Increase)/Decrease in Inventories	(1,383,717)	(1,689,730)	-	-
(Increase)/Decrease in Trade and Other Receivables	533,571	1,123,769	59,525	(209,431)
Increase/(Decrease) in Trade and Other Payables	(114,090)	(546,167)	110,048	359
<b>Cash Generated from Operations</b>	<b>1,844,470</b>	<b>1,302,014</b>	<b>81,777</b>	<b>(222,024)</b>
Finance Cost Paid	(188,042)	(324,558)	(51,506)	(59,333)
Finance Income Received	136,665	156,396	496	565
Income Tax Paid	(705,756)	(631,552)	(248)	(30,277)
Employee Retirement Benefit Paid	(37,626)	(47,930)	(458)	(624)
<b>Net Cash Flows From/(Used in) Operating Activities</b>	<b>1,049,711</b>	<b>454,370</b>	<b>30,061</b>	<b>(311,693)</b>
<b>Investing Activities</b>				
Purchase of Property, Plant and Equipment	(576,095)	(508,561)	(762)	(395)
Investment in Intangible Assets	(2,230)	2,527	-	-
Net Movement in Financial Assets	(2,375)	31,400	17,500	300,000
Investment in Joint Ventures/ Associate	(140,000)	-	-	-
Acquisition of /Investment in Subsidiaries	-	-	(145,000)	(76,400)
Investment Income Received	-	-	1	1
Proceeds on Disposal of Property, Plant and Equipment/ Intangible Assets	92,212	43,936	-	-
<b>Net Cash Flows From/(Used in) Investing Activities</b>	<b>(628,488)</b>	<b>(430,698)</b>	<b>(128,261)</b>	<b>223,206</b>
<b>Financing Activities</b>				
Interest-Bearing Loans and Borrowings (Net)	(464,478)	(265,315)	159,195	40,313
Exercise of ESOS	-	10,964	-	10,964
<b>Net Cash Flows From/(Used in) Financing Activities</b>	<b>(464,478)</b>	<b>(254,351)</b>	<b>159,195</b>	<b>51,277</b>
Net Increase/(Decrease) in Cash and Cash Equivalents	(43,255)	(230,679)	60,995	(37,210)
Net Foreign Exchange Difference	(33,830)	(29,892)	-	-
Cash and Cash Equivalents at the Beginning of the Period	12,261,325	11,812,583	19,815	(165,882)
<b>Cash and Cash Equivalents at the End of the Period</b>	<b>12,184,240</b>	<b>11,552,012</b>	<b>80,809</b>	<b>(203,092)</b>

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

## SEGMENTAL INFORMATION

Three Months Ended 30 June	Consumer Brands		Healthcare		Mobility		Others		Group	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
<b>Revenue from Contract with Customers</b>										
Segmental Revenue - Gross	8,665,302	8,923,490	21,483,077	17,400,491	506,173	487,097	577,325	530,075	31,231,877	27,341,153
Intra Segmental Revenue	(29,227)	(58,715)	(2,091,786)	(1,270,162)	(11,294)	(11,183)	(50,202)	(63,539)	(2,182,509)	(1,403,599)
Segment Revenue	8,636,075	8,864,775	19,391,291	16,130,329	494,879	475,914	527,123	466,536	29,049,368	25,937,554
Inter Segmental Revenue	-	-	-	-	-	-	(523,523)	(461,391)	(523,523)	(461,391)
<b>Total Revenue from Contract with Customers</b>	<b>8,636,075</b>	<b>8,864,775</b>	<b>19,391,291</b>	<b>16,130,329</b>	<b>494,879</b>	<b>475,914</b>	<b>3,600</b>	<b>5,145</b>	<b>28,525,845</b>	<b>25,476,163</b>
<b>Results</b>										
<b>Segmental Results</b>	<b>719,136</b>	<b>815,826</b>	<b>1,665,060</b>	<b>1,287,117</b>	<b>290,357</b>	<b>304,752</b>	<b>(559,117)</b>	<b>(487,036)</b>	<b>2,115,436</b>	<b>1,920,659</b>
Finance Cost	(25,601)	(39,689)	(193,782)	(281,554)	(10,992)	(1,191)	(20,707)	(51,560)	(251,082)	(373,994)
Finance Income	70,192	59,229	48,087	85,525	20,348	13,725	875	923	139,502	159,402
Share of Results of Equity Accounted Investees (Net of Tax)	-	-	-	-	7,817	150,568	(59,254)	(140,746)	(51,437)	9,822
<b>Profit/(Loss) before Tax</b>	<b>763,727</b>	<b>835,366</b>	<b>1,519,365</b>	<b>1,091,088</b>	<b>307,530</b>	<b>467,854</b>	<b>(638,203)</b>	<b>(678,419)</b>	<b>1,952,419</b>	<b>1,715,889</b>
Income Tax	(97,832)	(248,123)	(463,233)	(252,342)	(102,084)	(153,388)	(33,990)	(59,740)	(697,139)	(713,593)
<b>Profit/(Loss) for the Period</b>	<b>665,895</b>	<b>587,243</b>	<b>1,056,132</b>	<b>838,746</b>	<b>205,446</b>	<b>314,467</b>	<b>(672,193)</b>	<b>(738,159)</b>	<b>1,255,280</b>	<b>1,002,296</b>
<b>Attributable to:</b>										
Equity Holders of the Parent	665,605	586,124	1,050,166	827,923	148,315	269,671	(672,193)	(738,159)	1,191,893	945,559
Non-Controlling Interests	290	1,119	5,966	10,823	57,131	44,796	-	-	63,387	56,737
	665,895	587,243	1,056,132	838,746	205,446	314,467	(672,193)	(738,159)	1,255,280	1,002,296

All values are in LKR'000s, unless otherwise stated.

The above figures are provisional and subject to audit.

## SEGMENTAL INFORMATION

As at	Consumer Brands		Healthcare		Mobility		Others		Group	
	30.06.2025	31.03.2025	30.06.2025	31.03.2025	30.06.2025	31.03.2025	30.06.2025	31.03.2025	30.06.2025	31.03.2025
<b>ASSETS</b>										
<b>Non-Current Assets</b>										
Property, Plant and Equipment	6,514,341	6,460,433	14,018,463	13,943,192	60,378	59,630	778,250	793,812	21,371,432	21,257,067
Right of Use Assets	633,771	431,575	1,418,135	1,418,410	126,411	1,246	207,304	38,096	2,385,621	1,889,327
Investment Property	3,000	3,000	-	-	1,441,350	1,441,350	6,166,204	6,166,205	7,610,554	7,610,555
Other Non Current Financial Assets	34,331	40,613	190,298	134,197	-	-	111,430	103,022	336,059	277,832
Other Non Current Assets	6,229,134	6,230,847	1,724,699	1,738,254	1,444,172	1,436,381	28,166,591	27,942,427	37,564,596	37,347,909
<b>Segmental Non Current Assets</b>	<b>13,414,577</b>	<b>13,166,468</b>	<b>17,351,595</b>	<b>17,234,053</b>	<b>3,072,311</b>	<b>2,938,607</b>	<b>35,429,779</b>	<b>35,043,562</b>	<b>69,268,262</b>	<b>68,382,690</b>
Deferred Tax Assets									185,708	228,746
Eliminations/ Adjustments									(32,637,967)	(32,026,403)
<b>Total Non Current Assets</b>	<b>13,414,577</b>	<b>13,166,468</b>	<b>17,351,595</b>	<b>17,234,053</b>	<b>3,072,311</b>	<b>2,938,607</b>	<b>35,429,779</b>	<b>35,043,562</b>	<b>36,816,003</b>	<b>36,585,033</b>
<b>Current Assets</b>										
Other Current Financial Assets	1,365,356	1,366,832	967,071	788,110	81,561	12,973	526,371	535,941	2,940,359	2,703,856
Segmental Current Assets	20,180,391	19,400,865	36,852,088	36,793,287	5,464,773	5,399,973	1,036,367	986,906	63,533,619	62,581,031
Tax Refunds									285,149	301,130
Eliminations/ Adjustments									(5,776,128)	(5,353,652)
<b>Total Current Assets</b>	<b>21,545,747</b>	<b>20,767,697</b>	<b>37,819,159</b>	<b>37,581,397</b>	<b>5,546,334</b>	<b>5,412,946</b>	<b>1,562,738</b>	<b>1,522,847</b>	<b>60,982,999</b>	<b>60,232,365</b>
<b>Assets Held for Sale</b>	<b>11,231</b>	<b>73,128</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>11,231</b>	<b>73,128</b>
<b>Total Assets</b>	<b>34,971,555</b>	<b>34,007,293</b>	<b>55,170,754</b>	<b>54,815,450</b>	<b>8,618,645</b>	<b>8,351,553</b>	<b>36,992,517</b>	<b>36,566,409</b>	<b>97,810,233</b>	<b>96,890,526</b>
<b>Non Current Liabilities</b>										
Segmental Non Current Liabilities	1,141,728	1,085,211	2,472,564	4,594,257	108,862	58,647	405,066	440,498	4,128,220	6,178,613
Other Non-current Financial Liabilities		-	40	40	335	335	275,000	275,000	275,375	275,375
Deferred Tax Liability									3,537,799	3,473,577
Eliminations/ Adjustments									(5,051)	-
<b>Total Non Current Liabilities</b>	<b>1,141,728</b>	<b>1,085,211</b>	<b>2,472,604</b>	<b>4,594,297</b>	<b>109,197</b>	<b>58,982</b>	<b>680,066</b>	<b>715,498</b>	<b>7,936,343</b>	<b>9,927,565</b>
<b>Current Liabilities</b>										
Segmental Current Liabilities	8,321,422	7,633,585	27,283,606	25,811,321	3,715,111	3,706,149	5,716,999	3,128,316	45,037,138	40,279,371
Income Tax Liability									1,307,619	1,440,936
Eliminations/ Adjustments									(5,920,894)	(5,082,437)
<b>Total Current Liabilities</b>	<b>8,321,422</b>	<b>7,633,585</b>	<b>27,283,606</b>	<b>25,811,321</b>	<b>3,715,111</b>	<b>3,706,149</b>	<b>5,716,999</b>	<b>3,128,316</b>	<b>40,423,863</b>	<b>36,637,870</b>
<b>Liabilities associated with assets held for sale</b>	<b>4,659</b>	<b>4,659</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,659</b>	<b>4,659</b>
<b>Total Liabilities</b>	<b>9,467,809</b>	<b>8,723,455</b>	<b>29,756,210</b>	<b>30,405,618</b>	<b>3,824,308</b>	<b>3,765,131</b>	<b>6,397,065</b>	<b>3,843,814</b>	<b>48,364,865</b>	<b>46,570,094</b>
<b>Total Segment Assets</b>	<b>34,971,555</b>	<b>34,007,293</b>	<b>55,170,754</b>	<b>54,815,450</b>	<b>8,618,645</b>	<b>8,351,553</b>	<b>36,992,517</b>	<b>36,566,409</b>	<b>135,753,471</b>	<b>133,740,705</b>
<b>Total Segment Liabilities</b>	<b>9,467,809</b>	<b>8,723,455</b>	<b>29,756,210</b>	<b>30,405,618</b>	<b>3,824,308</b>	<b>3,765,131</b>	<b>6,397,065</b>	<b>3,843,814</b>	<b>49,445,392</b>	<b>46,738,018</b>
<b>Other Segmental Information</b>										
Acquisition Cost of property plant and equipment	231,048	1,095,850	336,519	3,849,768	4,702	51,033	3,826	83,443	576,095	5,080,094
Depreciation of segmental assets	159,565	595,338	243,010	820,006	3,954	23,589	43,936	149,810	450,465	1,588,743
Provision for Employee Benefit Liability	28,522	119,210	38,178	154,361	3,314	12,501	5,930	17,239	75,944	303,311
Impairment/Amortization of Intangible Assets	3,015	15,867	14,358	44,690	26	170	1,582	8,539	18,981	69,266
Amortisation of Right-of-Use Assets	19,359	92,547	64,233	208,581	2,830	18,344	7,019	20,203	93,441	339,675

All values are in LKR'000s, unless otherwise stated.  
The above figures are provisional and subject to audit.

## NOTES TO THE FINANCIAL STATEMENTS

### 1 Basis of Preparation

The condensed interim financial statements have been prepared in accordance with Sri Lanka Accounting Standard LKAS- 34, Interim Financial Reporting. The condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2025. Further, provisions of the Companies Act No. 7 of 2007 have been considered in preparing the interim financial statements.

Management is currently not aware of any material uncertainties that may cast significant doubt upon the Group's continuing performance.

### 2 Employee Share Option Scheme (ESOS)

#### (a) Employee Share Option Scheme (ESOS) - 2015

The Board of Directors, with the approval in principal of the Colombo Stock Exchange, and authorised by the shareholders at an Extraordinary General Meeting dated 10 April 2015, to create an Employee Share Option Scheme (ESOS) to offer 13,900,000 ordinary shares being 2.4% of the total number of shares in issue to Executive Directors and Senior Executives of the Company and its Subsidiaries whom the Board deems to be eligible to be awarded the shares.

Accordingly the options were granted to the Executive Directors and Senior Executives of the Company and its subsidiaries as follows,

	Date Of Grant	No of Shares Granted	Grant Price (LKR )	Vesting Period	No of Shares Vested	Exercise Period
<b>Grant 1</b>	27.07.2015	3,053,750	82.00	1 Year	2,574,423	3 Years
<b>Grant 2</b>	27.07.2016	3,008,750	87.50	1 Year	2,421,867	3 Years
<b>Grant 3</b>	27.07.2017	3,420,000	149.50	1 Year	2,034,796	3 Years
<b>Grant 4</b>	27.07.2018	3,491,250	108.81	1 Year	2,032,822	3 Years
<b>Grant 5</b>	27.07.2019	4,115,000	69.00	1 Year	2,204,212	3 Years
<b>Grant 6</b>	27.07.2020	2,630,758	60.00	1 Year	1,924,065	3 Years

#### (b) Employee Share Option Scheme (ESOS) - 2021

The Board of Directors, with the approval in principal of the Colombo Stock Exchange, and authorised by the shareholders at an Extraordinary General Meeting dated 30 June 2021, to create an Employee Share Option Scheme (ESOS) to offer 13,500,000 ordinary shares being 2.26% of the total issued and fully paid ordinary voting shares of the Company. The ESOS 2021 is applicable to Eligible Employees, who are employees of a company in the Hemas Group (i.e. the Company and subsidiaries of the Company as identified by the Board whose employees are eligible to participate in the Scheme)

The Grant Period under the ESOS 2021 shall commence on 20 July 2021 and end on 19 July 2026.

	Date Of Grant	No of Shares Granted	Grant Price (LKR )	Vesting Period	No of Shares Vested	Exercise Period
<b>Grant 1</b>	20.07.2021	3,538,112	82.46	1 Year	1,156,726	5 Years
<b>Grant 2</b>	20.07.2022	3,071,647	43.84	1 Year	927,454	5 Years
<b>Grant 3</b>	20.07.2023	3,375,000	71.02	1 Year	-	5 Years
<b>Grant 4</b>	01.10.2024	5,850,000	72.23	1 Year	N/A	5 Years

Under the Group's Employee Share Option Scheme (ESOS), share options of the parent are granted to executives of the Group/ Company generally with more than 12 months of service. The exercise price of the share options is equal to the 30 day volume weighted average market price of the underlying shares on the date of grant. The share options vested after period of one year from the date of grant and it depends on the performance criteria and time criteria. The fair value of the share options is estimated at the grant date using the Black Scholes option pricing model taking into account the terms and conditions upon which the share options were granted.

There are no cash settlement alternatives. The Group does not have a past practice of cash settlement for these share options.

### 3 Events After The Reporting Date

Other than those mention above, no circumstances have arisen since the reporting date, which would require adjustment to or disclosure in the financial statements.

### 4 There have been no significant changes in the nature of the contingent liabilities which were disclosed in the Audited Financial Statements for the year ended 31 March 2025.



## INVESTOR INFORMATION

	Three Months Ended 30 June	
	2025	2024
<b>Market Value of Shares</b>		
Closing Price on 30 June (LKR)	30.50	83.30
Last Traded Price on 30 June (LKR)	30.50	83.50
Highest Price During the Period (LKR)	123.00*	91.00
Lowest Price During the Period (LKR)	24.00	79.00
Market Capitalisation on 30 June (LKR Mn)	91,089	49,722
<i>*Highest price during the period is prior to the share subdivision.</i>		
<b>Ratios</b>		
Net Asset Per Share on 30 June (LKR)	16.35	14.26
Price Earnings Ratio on 30 June (Times)	19.11	13.15
<b>Share Trading</b>		
No of Transactions During the Period	22,923	5,606
No of Shares Traded During the Period	187,704,393	27,233,218
Value of Shares Traded During the Period (LKR Mn)	5,916	2,332
<b>Number of Shares</b>	<b>2,986,537,000</b>	596,906,402

*The share details for Q1 FY26 are post-share split.*

## SHARE INFORMATION

### List of 20 Major Shareholders as at 30 June

	2025		2024	
	No. of Shares	%	No. of Shares	%
1 A Z Holdings (Pvt) Ltd.	470,461,525	15.75	94,092,305	15.76
2 Amagroup (Pvt) Ltd.	457,136,665	15.31	91,427,333	15.32
3 Saraz Investments (Pvt) Ltd.	447,826,385	14.99	89,565,277	15.00
4 Blueberry Investments (Pvt) Ltd.	444,639,700	14.89	88,927,940	14.90
5 BBH-Kopernik Global All Cap Fund	65,748,685	2.20	16,019,905	2.68
6 Mrs. R.G. Abdulhussein	50,058,310	1.68	10,011,662	1.68
7 Mr. E.D. Pieris	48,358,216	1.62	-	-
8 J.B. Cocoshell (Pvt) Ltd	45,853,808	1.54	10,001,673	1.68
9 BBH-Kopernik Global All Cap Equity Fund	43,386,015	1.45	12,263,194	2.05
10 BBH-Tundra Sustainable Frontier Fund	35,009,640	1.17	7,001,928	1.17
11 Hatton National Bank PLC - Capital Alliance Quantitative Equity Fund	33,110,776	1.11	3,274,425	0.55
12 Rubber Investment Trust Ltd Account 1	31,935,990	1.07	8,145,002	1.36
13 BBH -Tundra Shikari Global	29,945,000	1.00	-	-
14 Est of Late Mr. M.J.Fernando	27,240,800	0.91	5,448,160	0.91
15 DFCC Bank PLC A/C 1	24,814,145	0.83	-	-
16 Akbar Brothers (Pvt) Ltd	21,822,375	0.73	3,968,420	0.66
17 Ranavav Holdings (Pvt) Ltd	18,540,175	0.62	-	-
18 Ceylon Investment PLC	17,533,595	0.59	3,706,719	0.62
19 Mellon Bank N.A-United Technologies CORP	17,497,350	0.59	5,488,757	0.92
20 Deutsche Bank AG As Trustee For JB Vantage Value Equity Fund	16,403,110	0.55	-	-

### Directors' Shareholding as at 30 June

	2025	2024
	No. of Shares	No. of Shares
<b>DIRECTORS' INDIRECT SHAREHOLDING</b>		
A Z Holdings (Pvt) Ltd.	470,461,525	94,092,305
Amagroup (Pvt) Ltd.	457,136,665	91,427,333
Saraz Investments (Pvt) Ltd.	447,826,385	89,565,277
Blueberry Investments (Pvt) Ltd.	444,639,700	88,927,940
<b>DIRECTORS' DIRECT SHAREHOLDING</b>		
Mr. H.N. Esufally (Chairman)	11,458,200	2,291,640
Dr. S.A.B Ekanayake (Deputy Chairman)	-	-
Ashish Chandra (CEO) - Appointed w.e.f 01 July 2025	-	-
Mr. A.N. Esufally	86,765	167,353
Mr. I.A.H. Esufally	431,420	2,086,284
Mr. M. A. H. Esufally	2,913,165	582,633
Mr.P. Subasinghe	-	-
Mr. Ranil Pathirana	-	-
Mr. W.V.S.D. Weerasinghe	-	-
Mr. W.A.T. Fernando	-	-
Ms. W.T.V. Perera	-	-
	1,834,953,825	369,140,765

### Public Holding as at 30 June

	2025	2024
Issued Share Capital (No. of Shares)	2,986,537,000	596,906,402
Public Holding as a % of Issued Share Capital	36.84%	36.89%
Total Number of Shareholders	10,721	7,642
Number of Shareholders representing the Public Holding	10,703	7,626

### Minimum Public Holding Requirement as per Listing Rules 7.13.1

	Float Adjusted Market Capitalisation - (LKR)	Public Holding Percentage	No of Shareholders	Option
Minimum Public Holding as at 30 June 2025	33,557,327,039	36.84%	10,703	1

---

## CORPORATE INFORMATION

### Legal Form

A limited Liability Company incorporated in Sri Lanka and listed on the Colombo Stock Exchange on 15th October 2003.

### Date of Incorporation

10 December 1948

### Date of Registration

30 May 2007

### Company Registration Number

PQ 6

### Accounting year end

31 March

### Registered Office

Hemas House  
No. 75, Braybrooke Place,  
Colombo 2.

### Website

[www.hemas.com](http://www.hemas.com)

### Telephone

+ 94 11 4731731

### Auditors

Ernst & Young  
Chartered Accountants  
Rotunda Towers, No.109, Galle Road, P.O. Box 101, Colombo 03.

### Directors

Husein Esufally (Chairman)  
Dr. Anura Ekanayake (Deputy Chairman)  
Ashish Chandra (CEO) - Appointed w.e.f 01 July 2025  
Abbas Esufally  
Imtiaz Esufally  
Murtaza Esufally  
Prabhash Subasinghe - Resigned w.e.f 31 July 2025  
Ranil Pathirana  
Ajith Fernando  
Supun Weerasinghe  
Thusitha Perera

### Secretaries

Hemas Corporate Services (Pvt) Ltd.  
No.75, Braybrooke Place, Colombo 02.  
Telephone: +94 11 4731731 (hunting)  
Facsimile: +94 11 4731777

### Registrars

SSP Corporate Services (Pvt) Ltd.  
No. 101, Inner Flower Road, Colombo 03.  
Telephone: +94 11 2573894, +94 11 2576871  
Email: [sspsec@sltnet.lk](mailto:sspsec@sltnet.lk)

### Lawyers to the Company

Group Legal  
Hemas Holdings PLC  
Hemas House, No 75, Braybrooke Place,  
Telephone: +94 11 4731731

### Investor Relations

Hemas Holdings PLC  
Hemas House, No 75, Braybrooke Place,  
Colombo 2  
Telephone: +94 11 4731731  
Email: [ir@hemas.com](mailto:ir@hemas.com)

### Bankers

Bank of Ceylon  
Citi Bank N.A.  
Commercial Bank of Ceylon PLC  
Deutsche Bank AG  
DFCC Bank PLC  
Hatton National Bank PLC  
National Development Bank PLC  
Nations Trust Bank PLC  
People's Bank  
Sampath Bank PLC  
Standard Chartered Bank  
Seylan Bank PLC  
The Hongkong & Shanghai Banking Corp. Ltd.  
Union Bank PLC